Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

JAMA : the Journal of the American Medical Association
Michael S SaagFTC-301A Study Team

Abstract

Emtricitabine is a new, once-daily nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against human immunodeficiency virus (HIV). To assess the efficacy and safety of emtricitabine as compared with stavudine when used with a background regimen of didanosine and efavirenz. Randomized, double-blind, double-dummy study conducted at 101 research clinics in North America, Latin America, and Europe. The first patient was enrolled on August 21, 2000; no investigator or patient was unblinded until the last patient randomized completed the week 48 visit on October 24, 2002. Analyses were based on data collected in a double-blind setting with a median follow-up of 60 weeks. Patients were 571 antiretroviral-naive, HIV-1-infected adults aged 18 years or older with viral load levels greater than or equal to 5000 copies/mL. Receipt of either 200 mg of emtricitabine once daily (plus stavudine placebo twice daily) (n = 286) or stavudine at standard doses twice daily (plus emtricitabine placebo once daily) (n = 285) plus open-label didanosine and efavirenz, once daily. Persistent virological response, defined as achieving and maintaining viral load at or below the limit of assay quantification (< or =400 or 50 copies/mL). At...Continue Reading

Citations

Feb 17, 2007·Dermatitis : Contact, Atopic, Occupational, Drug·Daniel D Miller, Erin M Warshaw
Feb 6, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A David PaltielRochelle P Walensky
Mar 12, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·UNKNOWN Antiretroviral Therapy Cohort Collaboration (ART-CC)Michael Saag
Sep 22, 2009·The Journal of Antimicrobial Chemotherapy·Franco Maggiolo
Jun 28, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Clotilde AllavenaUNKNOWN Bitherapy Kaletra-Sustiva Study Group
Jul 2, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·David J BackJohn G Gerber
May 3, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Mark OetteDieter Häussinger
May 3, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Ume L AbbasJohn W Mellors
Aug 2, 2007·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Evguenia S SvarovskaiaMichael D Miller
Jun 4, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Benjamin H ChiJeffrey S A Stringer
Nov 24, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Alondra López-MartínezJuan Sierra-Madero
Jul 4, 2006·Indian Journal of Pediatrics·Pimpanada ChearskulBasim Asmar
May 30, 2009·The Journal of Antimicrobial Chemotherapy·Michal Y ChowersMical Paul
Nov 3, 2010·The Journal of Antimicrobial Chemotherapy·Sébastien GallienUNKNOWN ALIZE (ANRS 099) Study Group
Sep 3, 2004·Drugs·Toni M Dando, Antona J Wagstaff
May 8, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M ChowersM Paul
Jan 14, 2005·Current Opinion in Infectious Diseases·Jussi Sutinen
Oct 6, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paul E SaxKenneth A Freedberg
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael S Saag
May 28, 2005·Expert Review of Anti-infective Therapy·Yves Benhamou
Dec 22, 2006·Expert Review of Anti-infective Therapy·Rosario PalaciosJesús Santos
Sep 9, 2009·Expert Review of Anti-infective Therapy·Ploenchan Chetchotisakd
Oct 3, 2006·Expert Review of Anti-infective Therapy·Rosa María Muñoz de Benito, Jose Ramón Arribas López
Feb 3, 2007·Expert Opinion on Pharmacotherapy·Miguel Goicoechea, Brookie Best
Oct 18, 2007·Expert Opinion on Pharmacotherapy·Gerrit Schreij, Robert Janknegt
Apr 22, 2008·Expert Opinion on Pharmacotherapy·Christoph Stephan
Mar 25, 2006·Expert Opinion on Pharmacotherapy·Brian G Gazzard
Apr 26, 2006·Expert Opinion on Emerging Drugs·Claude FortinPatrick Yeni
Jun 7, 2005·Expert Opinion on Emerging Drugs·Erik De Clercq
Mar 30, 2005·Expert Opinion on Drug Safety·David NolanSimon Mallal
Apr 22, 2005·Dermatologic Therapy·Heidi H Kong, Sarah A Myers
Jun 18, 2010·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de Expertos de Gesida, UNKNOWN Plan Nacional sobre el Sida

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.